Tandem Diabetes Care (NASDAQ:TNDM) highlighted its plans to expand insulin pump adoption through a shift to pharmacy distribution in the U.S., direct sales in additional international markets and upcoming product launches, including a tubeless version of its Tandem Mobi pump. Speaking at Canaccord’

Tandem Diabetes met Wall Street’s revenue and profit expectations in Q2, but the market responded negatively, likely reflecting investor caution around the pace of U.S. pump shipments and the near-term impact of the company’s business model transition. Management highlighted stronger pump shipment growth internationally and early traction from its new pharmacy channel in the U.S. CEO John Sheridan emphasized that the company’s ability to drive operational efficiencies and expand access to its te

Pump shipments surged 10% as pharmacy adoption accelerated.

Tandem Diabetes shares jump 19.1% after a narrower-than-expected Q2 loss, as higher pump shipments and a 57% gross margin offset a slight revenue miss.

Shares of diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) jumped 18.2% in the afternoon session after the company reported second-quarter results that showed improved profitability and a narrower-than-expected loss per share.

Diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) met Wall Street’s revenue expectations in Q2 CY2026, with sales up 5.8% year on year to $254.6 million. The company’s outlook for the full year was close to analysts’ estimates with revenue guided to $1.08 billion at the midpoint. Its non-GAAP loss of $0.31 per share was in line with analysts’ consensus estimates.

Tandem Diabetes Care reported past second-quarter 2026 results with record worldwide sales of US$254.56 million, higher gross margin of 57%, and a reduced net loss of US$21.17 million, while reaffirming full-year sales guidance of about US$1.07 billion. Momentum in the new PayGo pharmacy model, with roughly 10% of U.S. shipments and 45% formulary coverage, signaled a meaningful shift toward higher-visibility, recurring revenue streams and broader access for insulin pump users. Now we’ll...

Tandem Diabetes Care (TNDM) is back in focus after reporting second quarter 2026 results that paired record worldwide sales and a smaller net loss with reaffirmed full year sales guidance. See our latest analysis for Tandem Diabetes Care. The strong second quarter update has coincided with a sharp reversal in sentiment around Tandem Diabetes Care, with a 45.61% 1 month share price return and a 99.29% 1 year total shareholder return, even though the 3 year total shareholder return remains down...

Tandem Diabetes Care (TNDM) delivered a stronger underlying Q2 than the headline results suggested,

Tandem Diabetes Care (NASDAQ:TNDM) reported second-quarter results that included record sales, pump shipments and gross margin for a second quarter, while management highlighted early progress in its transition to pharmacy-channel reimbursement and continued development of new insulin-delivery techn

Moby summary of Tandem Diabetes Care, Inc.'s Q2 2026 earnings call

Tandem Diabetes Care (TNDM) delivered earnings and revenue surprises of +8.82% and -0.10%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Although the revenue and EPS for Tandem Diabetes Care (TNDM) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) met Wall Street’s revenue expectations in Q2 CY2026, with sales up 5.8% year on year to $254.6 million. The company’s outlook for the full year was close to analysts’ estimates with revenue guided to $1.08 billion at the midpoint. Its GAAP loss of $0.31 per share was in line with analysts’ consensus estimates.

Meridian Funds, managed by ArrowMark Partners, released its second-quarter 2026 investor letter for “Meridian Small Cap Growth Fund”. A copy of the letter can be downloaded here. The U.S. market saw a strong rally in the second quarter, fueled by easing geopolitical tensions, falling oil prices, and robust corporate earnings. Growth stocks, especially in technology and […]

Intuit downgrade, Intuitive Surgical upgraded: Wall Street's top analyst calls

The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to volatility as many lack the scale advantages of their larger peers.

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have realized strong financial performance, and over the past six months, the industry’s 10% return has closely followed the S&P 500.

Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, these businesses risk running out of capital or relying on dilutive fundraising.

The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how healthcare technology stocks fared in Q1, starting with Tandem Diabetes (NASDAQ:TNDM).